MIV-150 + LNG ring
Alternative Name: MZCL Combination IVR
Description: MIV-150 (an NNRTI that targets HIV) with zinc acetate (an antiviral agent with activity against HIV and HSV-2), carrageenan (an antiviral agent with activity against HPV) and levonorgestrel (LNG, a progestin) in an EVA or silicone vaginal ring.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Duration Type: Long-acting
Duration: 30 - 90 days
Dose: 10-70µg LNG (per day), MIV-150 ≥30µg; zinc acetate ≥100µg; carrageenan ≥500µg
Active Pharmaceutical Ingredient (API): - levonorgestrel
- MIV-150
- zinc acetate
- carrageenan
- levonorgestrel
- MIV-150
- zinc acetate
- carrageenan
Inactive material: EVA; silicone
Multipurpose Preventive Technology (MPT): Yes
Status Details
Developer: Population Council, ProMed Pharma
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Pre-clinical
Active Development: Unknown
Status Details: - Prototype macaque MZCL IVRs have undergone preclinical testing.
- Prototype macaque MZCL IVRs have undergone preclinical testing.
Additional Information
References: Derby N, et al. (2017) An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques. Drug Deliv. and Transl. Res.
Population Council Website: http://www.popcouncil.org/research/developing-arv-based-microbicide-and-...
Derby N, et al. (2017) An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques. Drug Deliv. and Transl. Res.
Population Council Website: http://www.popcouncil.org/research/developing-arv-based-microbicide-and-...